Asfand Yar Cheema/LinkedIn
Sep 4, 2025, 22:00
Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Asfand Yar Cheema, Cleveland Clinic
Presents results from a PSM cohort study evaluating the association of GLP-1 agonist therapy and key clinical outcomes in Polycythemia Vera.
GLP-1 agonist therapy is associated with significantly reduced risks of all-cause mortality, myelofibrosis progression, VTE, healthcare utilization, AKI, and ischemic stroke/TIA.
Randomized controlled trials are required to confirm GLP-1 agonist safety and efficacy in PV.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Nov 16, 2025, 19:46Ayodeji Olayanju: Academics Blood Matter Too!
-
Nov 16, 2025, 19:30Thomas Reiser Congratulates Saskia Middeldorp on Delivering the 2025 Sol Sherry Distinguished Lecture in Thrombosis
-
Nov 15, 2025, 15:47Shannon Farmer: Congratulations to Susan Goobie and Colleagues on Publication of Their Important Study
-
Nov 15, 2025, 15:46Fotios Barkas: Explore the Latest Articles From the Journal of Atherosclerosis Prevention and Treatment!
-
Nov 15, 2025, 15:45Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
-
Nov 15, 2025, 15:42Haroun Gajraj Thanks Enric Roche for Demonstrating the Piston Effect
-
Nov 15, 2025, 15:41Thrombectomy Rates Rise 700% Nationwide
-
Nov 15, 2025, 15:41Emmanuel J. Favaloro: Transitioning Patients from DOACs to Heparin
-
Nov 15, 2025, 15:40Bruno Lima: I Owe a Lot of My Career to Dr. Brad Maron